Nancy Lurker - 23 Jan 2024 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Executive Vice Chair, Director
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
23 Jan 2024
Net transactions value
-$874,200
Form type
4
Filing time
25 Jan 2024, 18:24:43 UTC
Previous filing
09 Jan 2024
Next filing
13 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Sale $125,950 -5,044 -3% $24.97 165,397 23 Jan 2024 Direct F1
transaction EYPT Common Stock Sale $748,250 -29,956 -18% $24.98 135,441 24 Jan 2024 Direct F2
holding EYPT Common Stock 52,208 23 Jan 2024 By Family Trust F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Stock Option (Right to Buy) Gift $0 -112,700 -25% $0.000000 338,100 24 Jan 2024 Common Stock 112,700 $3.26 Direct F4, F5
transaction EYPT Stock Option (Right to Buy) Gift $0 +112,700 $0.000000 112,700 24 Jan 2024 Common Stock 112,700 $3.26 By Family Trust F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.95 to $25.00. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.95 to $25.24. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F4 On January 24, 2024, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on January 6, 2023 and was exercisable for 112,700 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 112,700 shares of Common Stock of the Company.
F5 The option to purchase vests and becomes exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.